Entera Bio ( (ENTX) ) has released its Q4 earnings. Here is a breakdown of the information Entera Bio presented to its investors.
Entera Bio Ltd. is a clinical-stage company specializing in the development of oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform to address significant unmet medical needs in the biotechnology sector.
In its latest earnings report for the year ending December 31, 2024, Entera Bio highlighted a transformative year marked by significant advancements in its oral peptide programs, including the development of EB613 for osteoporosis and a partnership with OPKO Health for the oral GLP-1/Glucagon agonist program. The company also reported an increase in stockholder value and a strengthened balance sheet.
Key achievements for 2024 included progress in the EB613 program, with promising Phase 2 trial results and ongoing discussions with the FDA regarding regulatory endpoints. Entera also advanced its oral GLP-1/Glucagon and GLP-2 tablet programs, showcasing favorable pharmacokinetic profiles and potential benefits over existing therapies. Financially, the company reported a net loss of $9.5 million, with operating expenses slightly increasing from the previous year.
Looking ahead, Entera Bio aims to continue its mission of developing innovative therapies, with plans to initiate a Phase 3 study for EB613 and further its collaboration with OPKO Health. The company remains focused on execution and value addition, with sufficient cash reserves to fund operations into the third quarter of 2026.